India's Sun Pharma gets FDA nod for four generics

MUMBAI Jan 7 (Reuters) - India's Sun Pharmaceutical Industries Ltd (SUN.BO) said on Wednesday it has secured its first U.S. Food and Drug Administration approval to sell the generic version of a controlled substance in tablet form.

Sun said it had received approval to sell generic hydrocodone bitartate with acetaminophen in multiple strengths, which has a with a U.S. market size of $540 million for branded and generic versions.

It has also received approval for generic versions of cholesterol-fighting Lopid, Aredia, used to treat high blood calcium, and anti-allergent Phenargen in multiple strengths. (Reporting by Prashant Mehra; Editing by Mark Williams)